Heparină Sodică Rovi (Heparin Sodium)

Heparină Sodică Rovi is indicated for several antithrombotic purposes in clinical practice.

• Prevention and treatment of venous thromboembolism, including deep‑vein thrombosis and pulmonary embolism.
• Prophylaxis of clot formation during and after surgical procedures.
• Management of acute coronary syndromes such as unstable angina or myocardial infarction.
• Maintenance of catheter patency by reducing intraluminal thrombus formation.
• Use in patients requiring rapid anticoagulation during interventional cardiology procedures.

Adverse reactions to Heparină Sodică Rovi can vary in frequency and severity.

Common

• Minor bleeding at injection sites or from mucous membranes.
• Localized bruising or hematoma formation.
• Mild thrombocytopenia (platelet count reduction).
• Elevated liver enzymes without clinical symptoms.
• Transient rash or mild itching at the injection site.

Serious

• Major hemorrhage, including gastrointestinal or intracranial bleeding.
• Heparin‑induced thrombocytopenia (HIT) with paradoxical clotting.
• Severe allergic reactions such as anaphylaxis.
• Spontaneous spinal or epidural hematoma.
• Acute renal impairment secondary to bleeding complications.

When prescribing Heparină Sodică Rovi, clinicians should consider several safety factors.

• Assess baseline coagulation status and platelet count before initiating therapy.
• Use caution in patients with a history of bleeding disorders, recent surgery, or trauma.
• Monitor for signs of heparin‑induced thrombocytopenia, especially after 5–10 days of exposure.
• Adjust dose or discontinue in cases of uncontrolled bleeding or severe thrombocytopenia.
• Evaluate renal and hepatic function periodically during prolonged treatment.
• Avoid concurrent use with other anticoagulants or antiplatelet agents unless clinically justified.

Heparină Sodică Rovi may interact with various medications, influencing bleeding risk or anticoagulant effect.

Avoid

• Concurrent use with other anticoagulants (e.g., warfarin, direct oral anticoagulants) without close monitoring.
• Combination with antiplatelet drugs such as aspirin, clopidogrel, or NSAIDs that increase bleeding propensity.
• Use with fibrinolytic agents (e.g., alteplase) due to additive hemorrhagic risk.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may irritate gastric mucosa.
• Certain antibiotics (e.g., vancomycin) that can potentiate platelet dysfunction.
• Hormonal therapies (e.g., estrogen‑containing contraceptives) that modestly raise clot risk.
• High‑dose corticosteroids, which may affect wound healing and bleeding.